Short answer
Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q1 2026 results for quarter ended March 31, 2026, released April 29, 2026.
Anika Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026, released April 29, 2026
- Detailed financial results and management commentary available in Exhibit 99.1
- Earnings disclosure enables investors to assess quarterly operating performance and financial condition
Item 5.02 · Departure/Election of Directors or Officers
- William R. Jellison and Glenn R. Larsen resigning from the Board effective at the 2026 Annual Meeting
- Departures include all committee roles, with no reported disagreements involving the Company or management
- Board size decreasing from nine to seven members, reducing director representation and committee capacity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anika Therapeutics, Inc. 8-K filings
Get the next ANIK 8-K as it lands
Follow ANIK for push alerts, or ask the research agent what this filing means.